HOME >> BIOLOGY >> NEWS
Treatment With IL-2 Plus HAART Markedly Reduces HIV In Immune System "Hiding Places"

Individuals treated with interleukin-2 (IL-2) plus highly active antiretroviral therapy (HAART) have significantly fewer resting CD4+ T cells in their bloodstream which harbor HIV than patients receiving HAART alone, according to a study of 26 patients conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Resting CD4+ T cells are among the "safe havens" where HIV may persist for years - sewn into the cells' genes - despite aggressive three-drug antiretroviral therapy.

In resting CD4+ T cells taken from the bloodstream ("peripheral blood") of a small number of study patients receiving IL-2 plus HAART, the researchers have been unable to find HIV capable of replicating, even when they have looked for the virus in millions of cells with sensitive laboratory procedures.

Anthony S. Fauci, M.D., NIAID director and chief of the NIAID Laboratory of Immunoregulation (LIR), plans to present these new findings at the 36th Annual Meeting of the Infectious Diseases Society of America in Denver, Colo., on Sunday, November 15 at 8:30 a.m. Mountain Time. The lead LIR scientist on the new studies is Tae-Wook Chun, Ph.D., who, with Dr. Fauci and other colleagues, has published several seminal papers on latent reservoirs of HIV.

The NIAID team studied two different groups of HIV-infected patients, 12 receiving HAART (generally a combination of at least three antiretroviral drugs including a protease inhibitor) and 14 receiving HAART plus IL-2, administered either intravenously or subcutaneously. IL-2 is a regulatory protein of the immune system produced in the body by T cells. IL-2 has potent effects on the proliferation, differentiation and activity of a number of immune system cells, notably T cells. The 14 patients on HAART plus IL-2 received doses of IL-2 totaling 3 to 18 million international units per day during five-day treatment cycles, followed by a rest period of at least eight weeks before the next treatment cycle.

At the
'"/>

Contact: Greg Folkers
gfolkers@nih.gov
301-496-2263
NIH/National Institute of Allergy and Infectious Diseases
15-Nov-1998


Page: 1 2 3

Related biology news :

1. St. Petersburg/New Haven Partnership for HIV/AIDS Care, Treatment and Support launched
2. Treatment stimulates growth and regeneration of injured adult skeletal muscle
3. Treatment of lupus in mice may point the way to human treatment
4. Treatment in mice proves effective against Duchenne muscular dystrophy
5. Treatment protects mouse ovaries from radiation therapy
6. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
7. Treatment restores normal heart rhythm in patients
8. Researchers Develop New Treatment For Hepatitis B And C As Nation Anticipates Surge In Number Of Cases
9. Researchers: Exciting Discovery Might Improve Cancer Treatment
10. Coffee Without Addiction, Possible New Treatment For Osteoporosis, Wrinkle-Free Cotton, And More
11. Scientists Discover Molecular Trigger Of Mucus Production, Suggesting First Treatment For Deadly Bronchitis, Other Diseases

Post Your Comments:
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: